升高的甘油三-葡萄糖 (TyG) 指数预测严重病情的AECOPD患者的不良临床结果:一项回顾性研究
Xin Wang1, Xuerong Cui2, Huaping Fan3
1Department of Respiratory and Critical Care Medicine, Deyang People's Hospital, Deyang, Sichuan, 618099, People's Republic of China.
甘油三糖 (TyG) 指数与重症慢性肺炎患者的更差结果有关. 较高的TyG指数表明这些患者死亡,败血症,AKI和ARF风险增加.
科学领域:
- 关键护理医学 关键护理医学
- 代谢综合征是代谢综合征的一种.
- 呼吸系统医学 呼吸系统医学
背景情况:
- 三甘油-葡萄糖 (TyG) 指数是胰岛素耐药性的已知标志物.
- 它在COPD急性恶化 (AECOPD) 严重病患者的预后价值尚不清楚.
- 胰岛素耐药性越来越多地被认为是影响严重疾病结果的因素.
研究的目的:
- 调查TyG指数与AECOPD重病患者临床结果之间的关联.
- 确定TyG指数是否可以预测患者群体中的死亡率和其他并发症.
主要方法:
- 来自eICU协作研究数据库 (eICU-CRD) 的645名AECOPD患者的回顾性队列研究.
- 使用禁食甘油三和葡萄糖水平计算的TyG指数:Ln (禁食甘油三 (mg/dL) ×禁食血葡萄糖 (mg/dL) /2).
- 主要终点:住院和ICU死亡率. 二级终点:败血症,急性损伤 (AKI) 和急性呼吸衰竭 (ARF).
主要成果:
- 提升的TyG指数独立预测了增加的住院死亡率 (HR: 1.45) 和ICU死亡率 (HR: 2.13).
- 泰格指数还与更高的败血症风险相关 (OR:1.54),AKI (OR:1.57) 和ARF (OR:1.50).
- 卡普兰-梅尔分析和受限立方线证实了较高的TyG指数和死亡率增加之间的线性关系.
结论:
- 提升的TyG指数与重症AECOPD患者的不良临床结果显著相关.
- 泰格指数可以作为一个有价值的预后生物标志物,在这个严重疾病的人群.
- 需要进一步的前性研究来验证TyG指数用于预测重病AECOPD的预后.
更多相关视频
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
06:59Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
Published on: November 13, 2016
相关概念视频
Acute Pancreatitis II: Clinical Manifestations and Management
Hypoglycemia and Glucagon
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
